Measurements can help predict which tumors will respond to targeted therapies.
A new radiotracer can measure a tumor’s iron concentration, paving the way for iron-targeted treatments for cancer patients.
In a study published in the July issue of the Journal of Nuclear Medicine, a team of investigators revealed that the radiotracer 18F-TRX can accurately measure the iron concentration in a tumor with a dose similar to other 18F-based radiotracers, helping providers predict whether the cancer will respond to therapy.
Cancer cells rely on iron to have enough energy to grow. This gives them higher iron levels than healthy cells and has made the cytosolic ‘labile’ iron pool (LIP) of cancer cells an attractive target for treatment. But, there has been a need for a clear strategy for LIP measurement.
“LIP levels in patient tumors have never been quantified,” said Adam R. Renslo, Ph.D., professor in the pharmaceutical chemistry department at the University of California at San Francisco. “Iron rapidly oxidizes once its cellular environment is disrupted, so it can’t be quantified reliably from tumor biopsies. A biomarker for LIP could help determine which tumors have the highest LIP levels and might be especially vulnerable to LIP-targeted therapies.”
For their study, the team used 18F-TRX PET to image 10 tissue graft models of glioma and renal cell carcinoma in order to measure LIP, assessing tumor avidity and sensitivity to the radiotracer. They also used an animal model to determine effective human dosimetry.
According to their findings, 18F-TRX pinpointed tumor accumulation, accurately indicating LIP levels in tumors and identifying those that were most likely to responds to targeted treatments. In addition, they determined that pre-treatment 18F-TRX uptake also predicted treatment sensitivity.
“Iron dysregulation occurs in many human disorders, including neurodegenerative and cardiovascular disease, and inflammation,” said Michael J. Evans, associate professor in residence in UCSF’s radiology and biomedical imaging departments. “Applying 18F-TRX in the respective patient populations to define the extent of LIP expansion in affected tissues will be an important milestone toward understanding the therapeutic potential of LIP-targeted therapies beyond oncology.”
For more coverage based on industry expert insights and research, subscribe to the Diagnostic Imaging e-Newsletter here.
CT Study: AI Algorithm Comparable to Radiologists in Differentiating Small Renal Masses
May 14th 2024An emerging deep learning algorithm had a lower AUC and sensitivity than urological radiologists for differentiating between small renal masses on computed tomography (CT) scans but had a 21 percent higher sensitivity rate than non-urological radiologists, according to new research.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Study Finds High Concordance Between AI and Radiologists for Cervical Spine Fractures on CT
May 6th 2024Researchers found a 98.3 percent concordance between attending radiology reports and AI assessments for possible cervical spine fractures on CT, according to new research presented at the 2024 ARRS Annual Meeting.